- Home
- QSI vs PCRX Comparison
QSI vs PCRX Comparison
Compare QSI & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- PCRX
- Stock Information
- Founded
- QSI 2013
- PCRX 2006
- Country
- QSI United States
- PCRX United States
- Employees
- QSI N/A
- PCRX N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- PCRX Health Care
- Exchange
- QSI Nasdaq
- PCRX Nasdaq
- Market Cap
- QSI 226.8M
- PCRX 1.2B
- IPO Year
- QSI N/A
- PCRX 2011
- Fundamental
- Price
- QSI $1.33
- PCRX $26.51
- Analyst Decision
- QSI Strong Buy
- PCRX Buy
- Analyst Count
- QSI 3
- PCRX 6
- Target Price
- QSI $2.38
- PCRX $30.00
- AVG Volume (30 Days)
- QSI 5.6M
- PCRX 605.6K
- Earning Date
- QSI 11-11-2025
- PCRX 11-05-2025
- Dividend Yield
- QSI N/A
- PCRX N/A
- EPS Growth
- QSI N/A
- PCRX N/A
- EPS
- QSI N/A
- PCRX N/A
- Revenue
- QSI $3,412,000.00
- PCRX $705,848,000.00
- Revenue This Year
- QSI N/A
- PCRX $7.36
- Revenue Next Year
- QSI $219.33
- PCRX $10.07
- P/E Ratio
- QSI N/A
- PCRX N/A
- Revenue Growth
- QSI 100.47
- PCRX 2.25
- 52 Week Low
- QSI $0.61
- PCRX $13.04
- 52 Week High
- QSI $5.77
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- QSI 59.61
- PCRX 56.74
- Support Level
- QSI $0.95
- PCRX $26.22
- Resistance Level
- QSI $1.16
- PCRX $27.50
- Average True Range (ATR)
- QSI 0.08
- PCRX 0.93
- MACD
- QSI 0.04
- PCRX -0.09
- Stochastic Oscillator
- QSI 96.77
- PCRX 43.78
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.